Loading...

PROPHASE LABS INC US FDA Inspections 8-K Filing

PRPH

PROPHASE LABS INC

()

2026 8-K

Strategic Sale Initiated

Investor Webinar

Operational Update

Stock Uplisting Approved

Equity Agreement

Stock Structure Update

Director Resignation

Nasdaq Delisting Notice

Reverse Merger Proposed

Legal Counsel Update

Stock Split Announcement

Stock Split Announcement

Stock Split Action

Stockholder Meeting Results

Legal Unsealing Notice

Financial Results Update

Sales Agreement Signed

Strategic Advisory Agreement

Stockholder Approvals

Agreement Termination

Proxy Statement Update

Financial Results Release

Equity Offerings

Debt-Equity Swaps

Debt-Equity Swaps

Non-Compliance with Listing...

Financial Statements

Earnings Report

Earnings Update

Earnings Report

Earnings Report

Earnings Report

Earnings Report

Earnings Update

Earnings Report

Earnings Update

Earnings Report

Earnings Report

Earnings Report

Financial Results

Financial Results for Q3 2021

Quarterly Earnings Reports

Filing with Quantitative Data

Financial Performance

Financial Results

Quantitative Data

Financial Results for Q1 2021

Filing with Quantitative Data

Financial Results

Financial Results

Quarterly Earnings Reports

Quantitative Data

Quarterly Earnings Reports

External Links:

On January 22, 2026, ProPhase Labs, Inc. announced that its common stock has been approved for uplisting from the Pink Sheets to the OTCID Market, enhancing its trading visibility.

AI Assistant

PROPHASE LABS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.